Advancements in Dermatology: A Weekly Review
Dermatologia e Venerologia
Deucravacitinib in Plaque Psoriasis
Discussion of Dr. April Armstrong's research on deucravacitinib as a treatment for moderate to severe plaque psoriasis, comparing its efficacy and safety to placebo and apremilast.
Bibliography
1. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial.
Authors: Armstrong AW, Gooderham M, Warren RB, et al.
Journal: Journal of the American Academy of Dermatology, 2023 Jan
PMID: 35820547
DOI: 10.1016/j.jaad.2022.07.002
Authors: Armstrong AW, Gooderham M, Warren RB, et al.
Journal: Journal of the American Academy of Dermatology, 2023 Jan
PMID: 35820547
DOI: 10.1016/j.jaad.2022.07.002
